US Patent

US9750747 — Treatments involving eslicarbazepine acetate or eslicarbazepine

Method of Use · Assigned to Bail-Portela & Ca SA · Expires 2032-08-24 · 6y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects the use of eslicarbazepine acetate or eslicarbazepine in treating or preventing various disorders, including absence seizures.

USPTO Abstract

The invention provides a drug selected from eslicarbazepine acetate and eslicarbazepine, for use in treating or preventing a disorder selected from epilepsy, affective disorders, schizoaffective disorders, bipolar disorders, neuropathic pain and neuropathic pain related disorders, attention disorders, anxiety disorders, sensorimotor disorders, vestibular disorders, and fibromyalgia, in a patient suffering from or susceptible to absence seizures.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2041 — Aptiom
U-2121 — Aptiom
U-2121 — Aptiom
U-2041 — Aptiom

Patent Metadata

Patent number
US9750747
Jurisdiction
US
Classification
Method of Use
Expires
2032-08-24
Drug substance claim
No
Drug product claim
No
Assignee
Bail-Portela & Ca SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.